LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Longeveron Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$1.39+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $43.61M
P/E (TTM): –
Dividend yield: –

Longeveron Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	1.20	2.39	0.71	1.22	1.31	5.63
Cost of Revenue	0.40	0.51	0.49	0.73	0.72	3.80
Gross Profit	0.80	1.88	0.22	0.50	0.59	1.83
Research & Development	12	8.14	9.07	9.37	7.09	2.67
Selling, General & Admin	–	–	13	9.17	11	2.93
Selling & Marketing	–	–	0.78	1.05	1.21	0.20
General & Administrative	12	10	12	8.12	9.74	2.73
Operating Expenses	24	18	21	19	18	5.60
Operating Income	-23	-17	-21	-18	-17	-3.78
Interest Expense	–	–	–	1.40	0.00	0.01
Other Non-Operating Income	0.58	0.55	-0.38	-0.79	0.41	0.06
Asset Impairment Charges	0	0	0.30	–	–	–
Gain (Loss) on Investments	–	–	–	9.83	9,963	–
Gain (Loss) on Sale of Assets	-0.10	0	–	–	–	–
Income Tax Expense	0	0	0	0	–	–
Income from Continuing Operations	–	–	–	-19	-17	-3.72
Net Income incl. Noncontrolling Interests	–	–	–	–	-17	-3.72
Net Income	-23	-16	-21	-19	-17	-3.72
Net Income to Common	-23	-25	-22	-19	–	–
EPS (Basic)(per share)	-1.29	-2.62	-10.22	-9.00	-9.00	-2.30
EPS (Diluted)(per share)	-1.29	-2.62	-10.22	-9.00	-9.00	-2.30
Shares Outstanding (Basic, Weighted)(shares)	17,577	9,411	2,173	2.10	1.89	1.60
Shares Outstanding (Diluted, Weighted)(shares)	17,577	9,411	2,173	2.10	1.89	1.60
EBITDA	-22	-16	-20	-17	-17	-3.78

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 69.8%
Operating margin: -1992.8%
Net margin: -1977.6%
Return on equity, FY2025: -164.7%

Financial strength

Current ratio: 2.63
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 234.0%

Valuation

P/E ratio: –
Price to sales: 36.74
Price to book: 4.19
Dividend yield: –